Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer.
about
GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesisTherapeutic Implications of Targeting AKT Signaling in MelanomaGlycogen synthase kinase-3β is a pivotal mediator of cancer invasion and resistance to therapyGSK3A is redundant with GSK3B in modulating drug resistance and chemotherapy-induced necroptosisHyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cellsGlycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapyTCF/beta-catenin plays an important role in HCCR-1 oncogene expressionCharacterization and development of novel small-molecules inhibiting GSK3 and activating Wnt signaling.Identification of glycogen synthase kinase 3α as a therapeutic target in melanomaSpecific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growthHer2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha.Design, synthesis, and biological evaluation of novel EF24 and EF31 analogs as potential IκB kinase β inhibitors for the treatment of pancreatic cancerGSK-3 represses growth factor-inducible genes by inhibiting NF-kappaB in quiescent cells.IKK is a therapeutic target in KRAS-Induced lung cancer with disrupted p53 activity.P27(Kip1), regulated by glycogen synthase kinase-3β, results in HMBA-induced differentiation of human gastric cancer cells.Constitutive non-canonical NFkappaB signaling in pancreatic cancer cellsAkt pathway is hypoactivated by synergistic actions of diabetes mellitus and hypercholesterolemia resulting in advanced coronary artery disease.Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy.Glycogen synthase kinase-3β, NF-κB signaling, and tumorigenesis of human osteosarcoma.NF-κB addiction and its role in cancer: 'one size does not fit all'.Regulation of apoptosis by the circadian clock through NF-kappaB signaling.NF-kappaB and cancer: how intimate is this relationshipInsights into the interactions between maleimide derivates and GSK3β combining molecular docking and QSARCanonical and non-canonical NF-κB signaling promotes breast cancer tumor-initiating cellsDiscrete functions of GSK3α and GSK3β isoforms in prostate tumor growth and micrometastasis.Glycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression.Glycogen synthase kinase-3β regulates tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis via the NF-κB pathway in hepatocellular carcinoma.Cytoplasmic hnRNPK interacts with GSK3β and is essential for the osteoclast differentiation.Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the PancreasAberrant glycogen synthase kinase 3β in the development of pancreatic cancer.Oncogenic transcription factors: cornerstones of inflammation-linked pancreatic carcinogenesisNovel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis.Metabolic disorder, inflammation, and deregulated molecular pathways converging in pancreatic cancer development: implications for new therapeutic strategies.Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma.The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.Comparative analysis of Notch1 and Notch2 binding sites in the genome of BxPC3 pancreatic cancer cells.NF-kappaB as a therapeutic target in chronic lymphocytic leukemia.The ubiquitin-proteasome system and signal transduction pathways regulating Epithelial Mesenchymal transition of cancer.Glycogen Synthase Kinase 3β in Pancreatic Cancer and its Implications in Chemotherapy and Radiation Therapy.Glycogen synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells.
P2860
Q24319759-E6346DCD-C591-41EB-8CE6-5D7279306D0EQ24631438-882ACAE2-C053-4DDB-ACD4-4032AF1A30EEQ26739711-5360690C-A5C3-4E6C-88A3-085D1EEBF45AQ28540209-DA60C95B-F874-47F4-8C42-5446605F1E23Q30540051-2FEF5043-7AA4-49CF-ABC3-3BE8258D3696Q33437264-77DEA8B0-01D5-42EF-962F-70133BAE23E1Q33444348-5A9511F7-D2E3-4231-B3C6-E7D2751F9C11Q33510167-0E2ADCBB-CF19-4E4C-8E20-706D02FB8F49Q33569998-90C49D72-155F-44B3-B545-366889C8167FQ33631442-B1C6F42C-E947-4853-80EA-5454E02BD8E6Q33690338-4450B7CD-05CC-46D0-8A75-BB95047FD0EFQ33713919-7A874DBC-822B-4AD8-9007-6CF019CEF92BQ33717484-5B12FCA8-687C-4994-B5F9-A591ACC01AABQ33776852-30F40DE0-B534-4EBB-834A-9B8B64E050B8Q33856507-3BEDF51B-99F9-49CB-AC61-B007D2558CD1Q34021737-59333BF8-C7CE-43EC-B53F-A21F9E89AF9DQ34150587-B91E87AA-2F59-45E2-A98F-180FC497207BQ34585992-936D2E9C-FB36-482F-B3B3-2DDA3DCA6675Q34637826-84CC0EBE-BF92-4EB0-A620-B8386227C6A9Q35120893-5BBA6D98-47A9-46BA-8914-D62F25D9EF66Q35123146-BF085211-1EDD-42E2-805B-24C8DF5DC568Q35143597-1B072778-8A02-4E31-B5D2-B68E40087F60Q35204391-656A97FC-570E-4A67-A711-E6B768643ACAQ35586803-58770837-E1CC-400B-86C9-CCE4C887A479Q35742439-7ED69BA3-BE79-42E5-B15B-B1E7E0DEC1F4Q36019650-955EFE9E-C635-4041-B061-9CAAD0B83574Q36335972-A70B6D0A-6DB6-4D31-B960-1EF4A305BE7CQ36350166-8D6470B7-D388-411D-85DB-74EB811AE1EFQ36378003-2305B125-FA62-496A-9470-7E14BD40CE31Q36450022-ED870C9A-1798-4F02-BC5F-70AC7A18B766Q36516948-4A3D7F8B-47AA-488D-B4BA-C8657E54EC11Q37116160-89CD4A40-1521-4DA0-A46D-141D155A7797Q37129787-2D8A203E-EDA0-450F-BADD-2BBDA66EB6EBQ37481890-E3C73B8C-3CBF-4E6D-9F7F-9DDB714691B9Q37506648-53BD15B8-3477-4C83-B9DB-30800D3415F2Q37604313-EBBF7E24-FCF0-400E-AE18-9C21D7D795B9Q37690750-DDDB3FF0-AB08-4F6C-8D80-DF0135EA60C6Q38029132-8E3FBC75-A22A-48A8-948A-4A11973CB504Q38221504-D1C3FE67-D6C4-4B50-99A1-3FDA695F2C29Q38922877-C1FA0BAC-F9BA-4D8F-8CA7-E5BE06CF273D
P2860
Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Maintenance of constitutive Ik ...... pha/beta in pancreatic cancer.
@en
Maintenance of constitutive Ik ...... pha/beta in pancreatic cancer.
@nl
type
label
Maintenance of constitutive Ik ...... pha/beta in pancreatic cancer.
@en
Maintenance of constitutive Ik ...... pha/beta in pancreatic cancer.
@nl
prefLabel
Maintenance of constitutive Ik ...... pha/beta in pancreatic cancer.
@en
Maintenance of constitutive Ik ...... pha/beta in pancreatic cancer.
@nl
P2860
P1433
P1476
Maintenance of constitutive Ik ...... pha/beta in pancreatic cancer.
@en
P2093
Albert S Baldwin
Willie Wilson
P2860
P304
P356
10.1158/0008-5472.CAN-08-1061
P407
P577
2008-10-01T00:00:00Z